Evaluation of GM-CSF augmentation as a potential therapy in autoimmune PAP was initially prompted by the demonstration of restorative activities of this cytokine on impaired surfactant metabolism and innate immunity in GM-CSF deficient mice [25]. This evidence concerns the gene CSF2 and autoimmune pulmonary alveolar proteinosis.